ODTX
Odyssey Therapeutics, Inc.−0.17 (−0.77%) TodayNov 4, 10:44 AM ET
About ODTX
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
Company
- Headquarters
- Boston, MA
- Listed
- May 8, 2026
- Exchange
- Nasdaq
- Website
- odysseytx.com
- SEC industry
- Biological Products, (no Diagnostic Substances)
- Cylvex sector
- Health Care · Biotech
Biotech
- Market cap #42 of 146
Ranked highest first among stocks Cylvex covers.
- AMGNAmgen Inc$254.5B+2.05%
- GILDGilead Sciences Inc$212.7B+2.39%
- MRNAModerna Inc$98.73B+8.25%
- ARGXargenx SE$57.16B+0.87%
- RVMDRevolution Medicines, Inc.$41.96B+0.80%
Financial summary
Related companies
About
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
From company filings and market data · Not investment advice
Price data
From daily bars
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.